Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Greer, a developer of allergy immunotherapy products has launched a Phase III randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of sublingual-oral immunotherapy in adults with allergic rhinoconjunctivitis caused by short ragweed pollen.
Subscribe to our email newsletter
The trial is being conducted at 30 allergy specialty centers across the US and will enroll approximately 458 patients. Participants must be ages 18-50 and have a history of moderate to severe allergic rhinoconjunctivitis attributable to short ragweed pollen for at least two years. Patients with a history of mild intermittent asthma are eligible. The study will last approximately seven months.
Robert Esch, Greer’s executive vice president of R&D, said: “Our primary objective is to demonstrate that sublingual-oral immunotherapy (SLIT) using short ragweed extract prior to and during ragweed season reduces allergy symptoms and the need for anti-allergy medications. In addition to the symptom reduction scores, we will also conduct blood tests to determine if SLIT increases ragweed-specific antibody levels which would signal the presence of the same immunological markers that we see with traditional injection immunotherapy.”